Evidence map›Paper›PMID 36153971›Full record

ArticleACS synthetic biology2022

Reprogramming the Cleavage Specificity of Botulinum Neurotoxin Serotype B1.

Joseph D Cleveland, Amir Taslimi, Qi Liu, Anna M Van Keuren, Mair E A Churchill, Chandra L Tucker

Open access · greenAbstract read
In one paragraph

Article in ACS synthetic biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Joseph D ClevelandDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado 80045 United States.
Amir TaslimiDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado 80045 United States.
Qi LiuDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado 80045 United States.
Anna M Van KeurenDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado 80045 United States.ORCID 0000-0001-7034-101X
Mair E A ChurchillDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado 80045 United States.
Chandra L TuckerDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado 80045 United States.ORCID 0000-0003-3033-1786
University of Colorado Denver · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Uncovering new approaches to manipulate and probe biochemical processes with spatial and temporal precision.R35GM136367 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI Chandra L Tucker · 2020 to 2026
$3.0M
Validating and extending optical tools for extended neural silencingUF1NS107710 · NINDS · UNIVERSITY OF COLORADO DENVER · PI FORD, CHRISTOPHER PETER, KENNEDY, MATTHEW J · 2018 to 2018
$2.0M
Structural mechanisms of chromatin assemblyR01GM135604 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI CHURCHILL, MAIR E · 2020 to 2023
$1.7M
NCI NIH HHS P30 CA046934NIGMS NIH HHS R01 GM135604NIGMS NIH HHS R35 GM136367NINDS NIH HHS UF1 NS107710
6 · The paper itself

Abstract

Proteases with reprogrammed specificity for nonnative substrates are highly desired in synthetic biology and biomedicine. However, generating reprogrammed proteases that are orthogonal and highly specific for a new target has been a major challenge. In this work, we sought to expand the versatility of protease systems by engineering an orthogonal botulinum neurotoxin serotype B (BoNT/B) protease that recognizes an orthogonal substrate. We designed and validated an orthogonal BoNT/B protease system in mammalian cells, combining mutations in the protease with compensatory mutations in the protease substrate and incorporating a truncated target sequence and then demonstrated use of this orthogonal BoNT/B protease-substrate combination to regulate complex transcriptional circuitry in mammalian cells. Transposing this platform into yeast, we demonstrated utility of this approach for in vivo protease evolution. We tested this platform with the newly designed orthogonal protease and then used it in a high-throughput screen to identify novel orthogonal protease/protease substrate combinations. While carrying out this work, we also generated new cleavage reporters that could be used to report botulinum toxin protease activity in mammalian cells using simple fluorescent readouts. We envision that these approaches will expand the applications of botulinum protease in new directions and aid in the development of new reprogrammed proteases.

Indexed as

EndopeptidasesMammalsAnimalsProteolysisSerogroupSubstrate SpecificityEndopeptidasesbotulinum neurotoxincleavage reporterorthogonalproteasesubstratetranscriptional circuityeast screen

Identifiers

PMID36153971
PMCPMC9907380
OpenAlexW4297243536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.